Cipla has granted the global commercialization rights for its nasal spray ‘Dymista’ to Swedish partner Meda AB except for certain geographies. The two companies have extended an existing partnership for development under which Meda will have full coverage in all growth markets in Latin and South America, West Asia and Africa and Asia, including more than 120 new markets for the nasal spray prescribed for allergic rhinitis.
Under their extended agreement, both partners will collaborate on follow-up compounds for Dymista, capitalizing on intellectual property retained by both partners. Cipla will be responsible for formulation, while Meda will be responsible for clinical development, registration, marketing and sales. The companies will also collaborate on future production of Dymista and any new products developed.
Dymista is a novel nasal treatment of allergic rhinitis. Dymista was approved in the US in May 2012 and in Europe in January 2013.
